RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc.
Your view on RTGN
Overview
What the company does, where it operates, and who runs it.
About RetinalGenix Technologies Inc.
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jerry Katzman
- Headquarters
- 1450 North Mcdowell Boulevard, Apollo Beach, CA, US
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Jerry Katzman
- Headquarters
- 1450 North Mcdowell Boulevard, Apollo Beach, CA, US
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders.
Its products include the RetinalGeniX Imaging System, a diabetic non-mydriatic mass retinal imaging and screening device; and RetinalCam, a real-time in-home retinal monitoring, imaging, and physician alert system. The company was incorporated in 2017 and is headquartered in Petaluma, California.
RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for RetinalGenix Technologies Inc., and the rating behind it. RTGN last traded at $3.20; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for RetinalGenix Technologies Inc.. Starting points for RetinalGenix Technologies Inc.: EPS -$0.11, beta -3.95 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for RetinalGenix Technologies Inc.. RetinalGenix Technologies Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for RetinalGenix Technologies Inc.. Trailing twelve-month EPS for RetinalGenix Technologies Inc. stands at -$0.11. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for RetinalGenix Technologies Inc.. RetinalGenix Technologies Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
RetinalGenix Technologies Inc. valued side by side against its closest peers. RetinalGenix Technologies Inc. is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold RetinalGenix Technologies Inc., and how their positions are changing. At a $59.5M market value, institutional positions materially move RetinalGenix Technologies Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by RetinalGenix Technologies Inc. executives and directors. Shares of RetinalGenix Technologies Inc. have traded between $2.01 and $5.02 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming RetinalGenix Technologies Inc.. RetinalGenix Technologies Inc. is a $59.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming RetinalGenix Technologies Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for RetinalGenix Technologies Inc.. Coverage tracks RetinalGenix Technologies Inc. within Medical - Devices (Healthcare). Press releases and market coverage, newest first.